大体积脑转移瘤多分次放射外科治疗后的神经认知功能与生活质量:前瞻性临床试验结果
该前瞻性1期剂量递增试验纳入24例3-6cm完整或术后脑转移瘤患者,接受多分次立体定向放射外科治疗。15例完成基线与4个月神经认知评估,4个月时20%患者HVLT总回忆评分显著下降、33%无显著变化、47%显著改善,平均神经认知功能与生活质量评分至25个月末次评估时稳定或改善。
要点
- 大体积脑转移瘤多分次SRS后多数患者神经认知功能稳定或改善
- 4个月时47%患者HVLT总回忆评分显著改善,20%显著下降
- 平均神经认知与生活质量评分至25个月末次评估稳定或改善
核心结论
- 在接受剂量递增多分次SRS的大体积脑转移瘤可评估患者中,多数患者随访期间神经认知功能与生活质量稳定或改善。
研究设计与样本
- 2012至2021年开展的前瞻性1期剂量递增研究,纳入直径3至6cm完整或术后脑转移瘤患者,共24例接受治疗。
- 患者纵向完成HVLT、简易精神状态检查、FACT-Brain与Medical Outcomes Cognitive Scale评估,采用可靠变化指数评估HVLT从基线至4个月的变化,显著性定义为大于1个标准差变化。
主要发现
- 24例接受治疗患者中15例完成基线与4个月神经认知评估,中位年龄57岁(范围37-74岁),中位基线KPS 80(范围70-90),中位放疗靶区体积15.9 cm³(范围7.7-57.2 cm³)。
- 4个月时20%患者HVLT总回忆评分显著下降,33%无显著变化,47%显著改善。
- 平均神经认知功能与生活质量评分至25个月末次评估时稳定或改善。
- 无临床或治疗特征与神经认知功能或生活质量评分变化显著相关。
临床怎么用
- 对于3至6cm完整或术后脑转移瘤,多分次SRS后应纵向评估神经认知功能与生活质量,关注HVLT总回忆评分变化。
局限性
- 24例接受治疗患者中仅15例完成基线与4个月神经认知评估,可评估样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) is the standard of care for brain metastases, providing effective local tumor control while avoiding the neurocognitive effects of whole-brain radiation therapy. However, large brain metastases have been excluded from the randomized studies of single-fraction SRS, and there are limited data regarding neurocognitive outcomes with multifraction radiosurgery approaches for large intact or resected brain metastases. METHODS AND MATERIALS: We performed a prospective phase 1 dose-escalation study of multifraction SRS for intact or resected brain metastases 3 to 6 cm in diameter from 2012 to 2021. Patients longitudinally completed the Hopkins Verbal Learning Test (HVLT), Mini-Mental State Examination, Functional Assessment of Cancer Therapy-Brain, and Medical Outcomes Cognitive Scale. Reliable Change Index is used to assess HVLT change from baseline to 4 months. Significance is defined as greater than 1 SD change. Analysis of variance comparisons were performed for clinicodemographic characteristics associated with neurocognitive outcomes or quality-of-life metrics. RESULTS: Of the 24 patients treated in the trial, 15 completed both baseline and 4-month neurocognitive assessments. For the 15 patients with neurocognitive assessments, median age was 57 years (range, 37-74 years), median baseline Karnofsky Performance Status was 80 (range, 70-90), and median volume of radiation target was 15.9 cm3 (range, 7.7-57.2 cm3). At 4 months, 20% of patients had a significant decline in HVLT Total Recall scores, 33% had no significant change, and 47% had significant improvement. Mean neurocognitive function and quality-of-life scores were either stable or improved over time up to the last evaluation at 25 months. There were no clinical or treatment characteristics significantly associated with changes in neurocognitive function or quality-of-life scores. CONCLUSIONS: Of the evaluable patients with large brain metastases treated with dose-escalated, multifraction SRS, the majority of patients demonstrated stable or improved neurocognitive function and quality of life in follow-up.
引用
- Janopaul-Naylor JR, Reyes A, Cao Y, et al. Neurocognitive Function and Quality of Life After Multifraction Radiosurgery for Large Resected and Intact Brain Metastases: Results of a Prospective Clinical Trial. Adv Radiat Oncol. 2025. PMID: 41583334. doi:10.1016/j.adro.2025.101956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。